TY - JOUR
T1 - Functional autoantibodies in systemic sclerosis
AU - Günther, Jeannine
AU - Rademacher, Judith
AU - van Laar, Jakob M.
AU - Siegert, Elise
AU - Riemekasten, Gabriela
N1 - Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2015/9/4
Y1 - 2015/9/4
N2 - Functional autoantibodies are an emerging field of research that focuses on the effects of these immunoglobulins when they bind to their target molecules. Accumulating information now exists about the molecular targets and precise binding mechanisms of functional autoantibodies as well as about their downstream effects. These data raise the need to distinguish functional autoantibodies from non-functional autoantibodies with regard to their ability to stimulate or to inhibit their target protein via binding. The presence of autoantibodies has been documented in autoimmune disorders decades ago, but meanwhile, more and more autoantibodies have been identified as functional, acting as pathogenic drivers involved in the induction of organ-specific damage in systemic sclerosis as well as in other autoimmune disorders. These findings offer new opportunities for the development of novel therapeutic strategies.
AB - Functional autoantibodies are an emerging field of research that focuses on the effects of these immunoglobulins when they bind to their target molecules. Accumulating information now exists about the molecular targets and precise binding mechanisms of functional autoantibodies as well as about their downstream effects. These data raise the need to distinguish functional autoantibodies from non-functional autoantibodies with regard to their ability to stimulate or to inhibit their target protein via binding. The presence of autoantibodies has been documented in autoimmune disorders decades ago, but meanwhile, more and more autoantibodies have been identified as functional, acting as pathogenic drivers involved in the induction of organ-specific damage in systemic sclerosis as well as in other autoimmune disorders. These findings offer new opportunities for the development of novel therapeutic strategies.
UR - http://www.scopus.com/inward/record.url?scp=84940900420&partnerID=8YFLogxK
U2 - 10.1007/s00281-015-0513-5
DO - 10.1007/s00281-015-0513-5
M3 - Scientific review articles
C2 - 26292621
AN - SCOPUS:84940900420
SN - 1863-2297
VL - 37
SP - 529
EP - 542
JO - Seminars in Immunopathology
JF - Seminars in Immunopathology
IS - 5
ER -